Efficacy of Cetuximab After Treatment with Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor—Based Chemotherapy in Metastatic Colorectal Cancer

2006 ◽  
Vol 6 (1) ◽  
pp. 59-65 ◽  
Author(s):  
Jeffrey A. Meyerhardt ◽  
Denise Heseltine ◽  
Shuji Ogino ◽  
Jeffrey W. Clark ◽  
Peter C. Enzinger ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Metastatic Colorectal Cancer ◽  
Tyrosine Kinase Inhibitor ◽  
Receptor Tyrosine Kinase ◽  
Kinase Inhibitor ◽  
Growth Factor Receptor ◽  
Epidermal Growth

scholarly journals Novel approaches against epidermal growth factor receptor tyrosine kinase inhibitor resistance

Oncotarget ◽  
2018 ◽  
Vol 9 (20) ◽  
pp. 15418-15434 ◽  
Author(s):  
Carina Heydt ◽  
Sebastian Michels ◽  
Kenneth S. Thress ◽  
Sven Bergner ◽  
Jürgen Wolf ◽  
...  
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Tyrosine Kinase Inhibitor ◽  
Receptor Tyrosine Kinase ◽  
Kinase Inhibitor ◽  
Growth Factor Receptor ◽  
Epidermal Growth ◽  
Novel Approaches ◽  
Inhibitor Resistance

scholarly journals Investigation of the metabolic stability of olmutinib by validated LC-MS/MS: quantification in human plasma

RSC Advances ◽  
2018 ◽  
Vol 8 (70) ◽  
pp. 40387-40394 ◽  
Author(s):  
Mohamed W. Attwa ◽  
Adnan A. Kadi ◽  
Hany W. Darwish ◽  
Ali S. Abdelhameed
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Tyrosine Kinase Inhibitor ◽  
Receptor Tyrosine Kinase ◽  
Kinase Inhibitor ◽  
Growth Factor Receptor ◽  
Third Generation ◽  
Epidermal Growth ◽  
Egfr Tki

Olmutinib (OTB, Olita™) is an orally available third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI).

Sign in / Sign up

Export Citation Format

Share Document